Pfizer acquires Metsera for $47.50 per share upfront plus $22.50 in CVRs, gaining GLP-1 and combo obesity drugs in Phase 2

Roche is acquiring 89bio for $14.50 per share plus up to $6 in CVRs tied to ambitious milestones.

United Therapeutics rose on positive Phase 3 Tyvaso data in IPF, meeting endpoints with consistent benefits across subgroups.